At this time there is no evidence to suggest an interaction between the SARS-CoV-2 mRNA vaccines and Erivedge(r) [Vismodegib], nor other Gorlin syndrome manifestations. Clinical trials of all vaccines must first show they are safe and effective before any vaccine can be authorized or approved for use, including COVID-19 vaccines.
According to the CDC, the known and potential benefits of a COVID-19 vaccine must outweigh the known and potential risks of the vaccine for use under what is known as an Emergency Use Authorization (EUA). Genentech does note that due to rapid progress under the EUA, “there have been no specific studies conducted to examine the effectiveness of vaccines, in general, given to patients receiving vismodegib”. Experts continue to conduct more studies about the effect of COVID-19 vaccination on severity of illness from COVID-19, as well as its ability to keep people from spreading the virus that causes COVID-19.
COVID-19 can have serious, life-threatening complications, and there is no way to know how COVID-19 will affect you. And if you get sick, you could spread the disease to friends, family, and others around you. The CDC reports that all COVID-19 vaccines currently available in the United States have been shown to be highly effective at preventing COVID-19.
Click HERE to view clinical trial results and ongoing studies.
The Gorlin Syndrome Alliance (GSA) is pleased to share these articles in our continued efforts to provide information on Gorlin syndrome and its manifestations. The articles listed are available to all. The GSA takes no responsibility for their content, recommendations or information provided in these documents. They are presented simply as a service to our members seeking information. If you would like to provide other Gorlin syndrome related articles to the GSA, please email the GSA.